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We studied the molecular genetic basis of a C1
inhibitor deficiency in a patient with type I hereditary
angioneurotic edema using both the polymerase chain
reaction and nucleotide sequencing. A single nucleotide
change (T→A) at the GT 59 donor splice recognition
motif in the seventh intron of the C1 inhibitor gene
was detected. A restriction site analysis of the C1
inhibitor gene in the patient’s family indicated that this
mutation is correlated with a decreased level of C1
Hereditary angioneurotic edema (HANE) is a rareautosomal dominant transmitted disease, clinicallycharacterized by recurrent episodic nonpitting edemaof the skin and mucosal surface. Acute attacks mayresult in severe life threatening laryngeal edema
(Donaldson and Rosen, 1966). HANE results from a defect in
plasma serine protease C1 inhibitor (C1-INH) that plays a key role
in the control of the classical pathway of the complement system
and the activation of the intrinsic coagulation and kinin forming
system (Davis, 1988). According to the antigenic plasma level of
the C1-INH protein, two types of HANE have so far been
distinguished: a quantitative defect and a qualitative defect. Type I
HANE is characterized by low antigenic and functional plasma
levels of the C1-INH protein. These patients represent the majority
(85%) of HANE patients. In contrast, type II HANE is characterized
by the presence of normal or elevated antigenic levels of a
dysfunctional mutant protein together with reduced levels of the
functional protein (Rosen et al, 1971; Gadek et al, 1979). Because
HANE is transmitted as an autosomal dominant trait, the disruption
of one allele of the C1-INH gene can cause HANE. In this study,
we report a case of type I HANE with a point mutation at the
59 donor mRNA splice site of the seventh intron of the C1-INH gene.
MATERIALS AND METHODS
Patient A 42 y old Japanese female had had symptoms of HANE since
she was 19 y old. The serum amount of C1-INH protein was reduced
(5 mg per dl, normal range 14–30 mg per dl). The C1-INH functional
activity was less than 25% (normal range 80–125%). A low serum level of
C2 and C4 was observed (C2, 1.0 mg per dl, normal range 1.6–3.6 mg
per dl; C4, 4 mg per dl, normal range 18–39 mg per dl) but the serum
Manuscript received June 6, 1997; revised November 30, 1997; accepted for
publication January 7, 1998.
Reprint requests to: Dr. Yasuhiro Kawachi, Department of Dermatology,
Institute of Clinical Medicine, University of Tsukuba, 1-1-1, Ten-nodai,
Tsukuba, Ibaraki 305, Japan.
Abbreviations: C1-INH, C1 inhibitor; HANE, hereditary angioneurotic
edema.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
837
inhibitor activity. A northern blot analysis demonstrated
C1 inhibitor mRNA to have a normal size, but its
contents were reduced by about 50% compared with
a normal subject. As the donor splice site is essential
for an excising of the intron during mRNA processing,
aberrant mRNA splicing may cause a rapid degradation
of the transcript, thus resulting in the onset of hereditary
angioneurotic edema. Key words: direct sequencing/point
mutation. J Invest Dermatol 110:837–839, 1998
level of C1q and C3 was within the normal range. The patient’s son, 11 y
old, also showed a reduction in the serum amount as well as the functional
activity of C1-INH, C2, and C4, but no symptoms of HANE were
observed. All other members of her family had no symptoms of HANE.
In addition, her parents, brothers, and daughter all showed a normal serum
amount and normal functional activity of C1-INH.
Preparation of genomic DNA and a Southern blot analysis White
blood cells were isolated from peripheral blood and high molecular weight
genomic DNA was extracted as previously described (Whitehead et al,
1984). Ten microgram aliquots of DNA were digested with BclI, and
subjected to 1.5% agarose gel electrophoresis. The Southern blot analysis
method used has been previously described (Southern, 1975) using 32P-
labeled C1-INH cDNA as a probe.
Amplification of the exons of the C1 inhibitor gene A polymerase chain
reaction (PCR) was used to amplify all eight exons including the flanking
introns of the C1-INH gene from genomic DNA. PCR amplification was
performed using 1 U of Taq polymerase (Amersham Life Science, Cleveland,
OH) according to the protocol described in the GeneAmp DNA amplification
kit (Perkin-Elmer, Foster City, CA). In the amplification process, 100 ng of
genomic DNA was denatured for 1 min at 94°C, followed by 30 amplification
cycles of denaturation for 0.5 min at 94°C, annealing for 0.5 min at 56°C, and
extension for 1 min at 72°C. At the end of the 40 cycles, an additional
extension was carried out at 72°C for 10 min. The oligonucleotide primers
used are listed in Table I.
Restriction site analysis of PCR amplified exon 7–intron 7
boundary Because the T→A mutation at the donor splice site of the
exon 7–intron 7 boundary results in loss of restriction site for HphI, aliquots of
the PCR amplified 312 bp fragment of the exon 7–intron 7 boundary of the
C1 inhibitor gene were digested with HphI. The digested products were
subjected to 1.5% agarose gel electrophoresis and stained with ethidium bromide.
Primers used in the PCR were: 59-TCCTGGTACCCCAGAACCTG-39
(forward primer in exon 7), 59-AACTTGCAGGGTTGCAGGAC-39 (reverse
primer in intron 7).
Preparation of RNA and northern blot analysis Total cellular RNA was
isolated from adherent monocyte monolayers (Einstein et al, 1976) by lysis with
guanidium thiocyanate and phenol (Isogen RNA extraction kit, Nippongene,
Tokyo, Japan). Ten micrograms of total RNA was denatured with formaldehyde
and formamide and separated by electrophoresis in formaldehyde containing
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Table I. The oligonucleotide primers used for the PCR amplification
of all eight exons including the flanking introns of the C1
inhibitor gene
Primer 59
no. Exon no. Primer sequence (59→39) Position
1 Exon 1,2 Forward TACAGGAACTCACACCAGCG 2125
2 Reverse TTAATCCTCAGCCACCGCCC 702
3 Exon 3 Forward TTTAGAGGACTGTGCCTCG 2137
4 Reverse GGCTTTGTAAGTCTGG 2756
5 Exon 4 Forward CTCCAAAGCAGGGAATACC 4261
6 Reverse GGTCTTCACCTGCTCTGCAG 4606
7 Exon 5,6 Forward CTCCACCATGCCGTATTCA 8198
8 Reverse GGCTAGAGAAAGGAGAAGGAG 9006
9 Exon 7 Forward CAGACTGCAGGACAGCATTG 13942
10 Reverse AACTTGCAGGGTTGCAGGAC 14361
11 Exon 8 Forward CTGGGACTCAGGATGAACCC 16540
12 Reverse CAAGTCCAGGCAGGCAGCAG 16959
Figure 1. Southern blot analysis of the patient with HANE and a
normal unaffected person. BclI digested genomic DNA was hybridized with
a C1-INH cDNA probe. Lane 1 contains the control DNA of an unaffected
person whereas lane 2 contains the DNA of a patient with HANE.
1% agarose gel. Samples were transferred to nylon membrane and hybridized
with 32P-labeled C1-INH cDNA.
DNA sequencing The PCR products were directly sequenced by the dye
labeled dideoxy termination method using a dye terminator cycle sequencing
kit (Perkin-Elmer).
RESULTS AND DISCUSSION
The C1-INH gene has BclI sites at both ends, 21 kb apart (Skriver
et al, 1989). Using the BclI enzyme for digestion in the Southern blot
analysis, the patient’s C1-INH gene showed a single hybridized 21 kb
band identical to the normal control DNA (Fig 1). This finding
demonstrates that neither a large deletion nor a rearrangement in the
patient’s C1-INH gene are responsible for the disease.
A direct sequence analysis of the PCR amplified DNA revealed the
a single base change (T→A) at nucleotide 14252 (Carter et al, 1991)
in comparison with the normal allele sequence (Fig 2A, B). To confirm
Figure 2. Direct nucleotide sequencing of the PCR amplified DNA
around the exon 7–intron 7 boundary. (A) The sense direction (from 59 to
39) sequence of the patient DNA. The patient DNA has two alleles and a
comparison of the mutant allele and the normal allele reveals a single base
substitution T→A as indicated by the arrow. (B) The sense direction sequence
of the unaffected person DNA. No mismatches between the two alleles are
seen. (C) The anti-sense direction (from 39 to 59) sequence of the patient
DNA. The A→T substitution corresponding to the T→A substitution in (A)
is detected as indicated by the arrow.
Figure 3. HphI RFLP analysis of the PCR amplified exon 7–intron 7
boundary. Aliquots of the PCR amplified 312 bp fragment of the seventh
exon–intron junction of the C1 inhibitor gene were digested with HphI. The
digested products were subjected to 1.5% agarose gel electrophoresis and stained
with ethidium bromide. M, molecular weight marker; 1 kb ladder (Gibco
BRL, Gaithersburg, MD); lane 1, the patient’s DNA; lane 2, the son’s DNA;
lane 3, the daughter’s DNA; lane 4, normal control DNA.
this point mutation, direct sequencing from a reverse direction (from
39 to 59) was performed, and a point mutation (A→T) corresponding
to the T→A mutation was thus detected (Fig 2C). No other sequence
mismatches of the two alleles of the C1-INH gene were detected. To
confirm that this T→A mutation is responsible for the susceptibility
to HANE in the patient’s family, the C1-INH genes of the patient,
her subclinically affected son, her healthy daughter, and a normal
volunteer were examined regarding this mutation using a restriction
fragment length polymorphism analysis. When the exon 7–intron 7
junction was amplified by PCR using an exon 7 forward primer and
an intron 7 reverse primer, a 314 bp band was thus produced. The
T→A mutation disrupts the HphI restriction enzyme recognition site
(GGTGA) on the exon 7–intron 7 boundary. In normal subjects, the
digestion with HphI generated two fragments of 183 bp and 129 bp,
respectively, although only a faint undigested band was seen (Fig 3,
lane 4). In the patient, an undigested 312 bp band, in addition to the
digested 183 bp and 129 bp bands, was generated, indicating that the
PCR products from the normal allele were digested, whereas the
products from the mutant allele remained undigested (Fig 3, lane 1).
The HphI digestion pattern obtained from the patient’s son was
identical to that from the patient (Fig 3, lane 2), and the healthy
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Figure 4. Northern blot analysis of C1-INH mRNA. The total RNA
extracted from peripheral blood monocytes obtained from the patient (lane 1)
and normal volunteer (lane 2) was hybridized with 32P-labeled C1-INH cDNA.
To normalize the amount of RNA, a photograph of the ethidium bromide
stained gel is shown under the corresponding lanes. 18S indicates the 18S
rebosomal RNA.
daughter also showed an identical pattern to that of the normal
volunteer (Fig 3, lane 3).
The mutated T residue is the second nucleotide of the intron 7 and,
as such, constitutes part of the GT 59 donor splice site recognition
motif essential for the excision of the intron 7 during C1-INH mRNA
processing. The GT dinucleotide at the 59 donor splice site is involved
in the binding of the U1 small nuclear ribonucleoprotein particles and
thus forms a cleavage site in the spliceosome for correct lariat formation
(Lamond et al, 1987). Mutations at this conserved GT dinucleotide
diminish the degree of correct splicing and also promote the aberrant
joining of exons (Padgget et al, 1986). As a result, the 59 donor splice
site mutation of the intron 7 of the C1-INH gene in this case abolished
the correct splicing of the intron 7 and thus created the aberrant
translation termination codon, UAG, or unstable immature C1-INH
mRNA that is scarcely translated and therefore produces type I HANE.
We amplified the exon 7–intron 7 boundary of C1-INH mRNA by
reverse transcriptase PCR using both a forward primer in exon 7 and
a reverse primer in intron 7 to identifiy the aberrantly spliced exon 7–
intron 7 hybrid transcript; however, no PCR product was generated
(data not shown). A northern blot analysis revealed a decreased level
of C1-INH mRNA in the patient (Fig 4). Densitometric scanning
of the film indicated the intensity of the band to be about half that
of the normal counterpart. Despite its decreased content, the size of
C1-INH mRNA obtained from the patient was identical to that of
the normal volunteer. These results suggest that the transcript from
this mutant allele is both unstable and tends to degrade rapidly.
A limited number of the C1-INH gene mutations responsible for
type I HANE have been described and include an exon deletion
(Stoppa-Lyonnet et al, 1990), a single base deletion in exon 8 (Siddique
et al, 1992), and a point mutation of exon 8 (Siddique et al, 1993). As
exon 8 includes the functional catalytic center of C1-INH, the
mutations in exon 8 are the most frequently previously reported
mutations. Only one case of an mRNA splice site mutation in the
sixth intron of the C1-INH gene has been reported in type I HANE
(Siddique et al, 1991). This form of mutation is well recognized as a
cause of several hereditary diseases, including ornithine transcarbamylase
deficiency (Oppliger et al, 1996), trifunctional protein deficiency
(Brackett et al, 1995), and familial lipoprotein lipase deficiency (Gotoda
et al, 1991). All of these mutations occur at the first nucleotide G in
the consensus sequence GT. Our case is also unique in that the
mutation was seen at the second nucleotide T.
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